Legalizing marijuana

Journal of Psychiatry and Neuroscience

Volumn 41, Issue 2, 2016, Pages 75-76

  Leyton, Marco ^a,b,c,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c and Applied Physiology   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ANABOLIC AGENT; CANNABIDIOL; CANNABIS; TETRAHYDROCANNABINOL;

ALCOHOL INTOXICATION; CANNABIS ADDICTION; CANNABIS USE; COCAINE DEPENDENCE; COGNITIVE DEFECT; EDITORIAL; HEROIN DEPENDENCE; HUMAN; LEGAL ASPECT; MULTIPLE SCLEROSIS; NAUSEA; PSYCHOMOTOR DISORDER; PSYCHOSIS; SCHIZOPHRENIA; TOBACCO USE; CANADA; DRUG LEGISLATION; RISK; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

CANADA; CANNABIS; HUMANS; LEGISLATION, DRUG; RISK; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 84966599708     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.160012     Document Type: Editorial

References (28)

1. Silins E, Horwood LJ, Patton GC, et al.; Cannabis Cohorts Research Consortium. Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry 2014;1:286-93.
2. George TP, Vaccarino F. The effects of cannabis use during adolescence. Canadian Centre on Substance Abuse; 2015. Available: www.ccsa.ca/Resource%20Library/CCSA-Effects-of-Cannabis-Use-during-Adolescence-Report-2015-en.pdf (accessed 2015 June 9).
3. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A 2012;109:E2657-64.
4. Anthony JC. The epidemiology of cannabis dependence. In: Roffman RA & Stephens RS (eds.), Cannabis dependence: its nature, consequences and treatment. Cambridge (UK): Cambridge University Press; 2006, pp. 58-105.
5. Bosker WM, Karschner EL, Lee D, et al. Psychomotor function in chronic daily cannabis smokers during sustained abstinence. PLoS ONE 2013;8:e53127.
6. Kosten TR, O’Connor PG. Management of drug and alcohol withdrawal. N Engl J Med 2003;348:1786-95.
7. Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res 2007;9:315-27.
8. Pagliaccio D, Barch DM, Bogdan R, et al. Shared predisposition in the association between cannabis use and subcortical brain structure. JAMA Psychiatry 2015;72:994-1001.
9. Zalesky A, Solowij N, Yücel M, et al. Effect of long-term cannabis use on axonal fibre connectivity. Brain 2012;135:2245-55.
10. Bloomfield MAP, Morgan CJA, Egerton A, et al. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 2014;75:470-8.
11. Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA 2015;313:2474-83.
12. Hall W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction 2015;110:19-35.
13. Di Forti M, Marconi A, Carra E, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2015; 2:233-8.
14. Gage SH, Zammit S, Hickman M. Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. F1000 Med Rep 2013;5:2.
15. Hickman M, Vickerman P, Macleod J, et al. If cannabis caused schizophrenia — How many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations. Addiction 2009;104:1856-61.
16. Gage SH, Hickman M, Heron J, et al. Associations of cannabis and cigarette use with psychotic experiences at age 18: findings from the Avon Longitudinal Study of Parents and Children. Psychol Med 2014;44:3435-44.
17. Nutt DJ, King LA, Phillips LD, et al. Drug harms in the UK: a multicriteria decision analysis. Lancet 2010;736:1558-65.
18. Pryce S. Fixing drugs: the politics of drug prohibition. UK: Palgrave Macmillan; 2012.
19. Room R, Fischer B, Hall W, et al. Cannabis policy: moving beyond the stalemate. Oxford (UK); Oxford University Press & The Beckley Foundation; 2010.
20. Centre for Addiction and Mental Health. Cannabis policy framework; 2014. Available: www.camh.ca/en/hospital/about_camh/influencing_public_policy/Documents/CAMHCannabisPolicyFramework.pdf (accessed 2015 Oct. 7).
21. Khenti A. The Canadian war on drugs: structural violence and unequal treatment of black Canadians. Int J Drug Policy 2014;25:190-5.
22. Werb D, Nosyk B, Kerr T, et al. Estimating the economic value of British Columbia’s domestic cannabis market: implications for provincial public policy. Int J Drug Policy 2012;23:436-41.
23. Ogrodnik M, Kopp P, Bongaerts X, et al. An economic analysis of different cannabis decriminalization scenarios. Psychiatr Danub 2015;27(Suppl 1):S309-14.
24. Support for marijuana legalization steady at more than half. In: Forum Research [website]; 2015 Available: http://poll.forumresearch.com /post/1362 /just-one-tenth-think-current-laws-are-appropriate/ (accessed 2015 Sept. 20).
25. Canadian Centre on Substance Abuse (CCSA). Cannabis regulation: lessons learned in Colorado and Washington State. Ottawa (ON): CCSA; 2015. Available: www.ccsa.ca/Resource%20Library/CCSA-Cannabis-Regulation-Lessons-Learned-Report-2015-en.pdf (accessed 2015 Nov. 13).
26. Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry 2015;72:1235-42.
27. Hall W, Weier M. Assessing the public health impacts of legalizing recreational cannabis use in the USA. Clin Pharmacol Ther 2015;97:607-15.
28. Canadian Centre on Substance Abuse (CCSA). Marijuana for Non-Therapeutic Purposes. Ottawa (ON): CCSA; 2014. Available: www.ccsa.ca/Resource%20Library/CCSA-Non-Therapeutic-Marijuana-Policy-Brief-2014-en.pdf (accessed 2015 Oct. 21).